Cargando…
Age-Dependent in vitro Maturation Efficacy of Human Oocytes – Is There an Optimal Age?
In vitro maturation of oocytes from antral follicles seen during tissue harvesting is a fertility preservation technique with potential advantages over ovarian tissue cryopreservation (OTC), as mature frozen and later thawed oocyte used for fertilization poses decreased risk of malignant cells re-se...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8250136/ https://www.ncbi.nlm.nih.gov/pubmed/34222236 http://dx.doi.org/10.3389/fcell.2021.667682 |
_version_ | 1783717026301214720 |
---|---|
author | Karavani, Gilad Wasserzug-Pash, Peera Mordechai-Daniel, Talya Bauman, Dvora Klutstein, Michael Imbar, Tal |
author_facet | Karavani, Gilad Wasserzug-Pash, Peera Mordechai-Daniel, Talya Bauman, Dvora Klutstein, Michael Imbar, Tal |
author_sort | Karavani, Gilad |
collection | PubMed |
description | In vitro maturation of oocytes from antral follicles seen during tissue harvesting is a fertility preservation technique with potential advantages over ovarian tissue cryopreservation (OTC), as mature frozen and later thawed oocyte used for fertilization poses decreased risk of malignant cells re-seeding, as compared to ovarian tissue implantation. We previously demonstrated that in vitro maturation (IVM) performed following OTC in fertility preservation patients, even in pre-menarche girls, yields a fair amount of oocytes available for IVM and freezing for future use. We conducted a retrospective cohort study, evaluating IVM outcomes in chemotherapy naïve patients referred for fertility preservation by OTC that had oocyte collected from the medium with attempted IVM. A total of 133 chemotherapy naïve patients aged 1–35 years were included in the study. The primary outcome was IVM rate in the different age groups – pre-menarche (1–5 and ≥6 years), post-menarche (menarche-17 years), young adults (18–24 years) and adults (25–29 and 30–35 years). We demonstrate a gradual increase in mean IVM rate in the age groups from 1 to 25 years [4.6% (1–5 years), 23.8% (6 years to menarche), and 28.4% (menarche to 17 years)], with a peak of 38.3% in the 18–24 years group, followed by a decrease in the 25–29 years group (19.3%), down to a very low IVM rate (8.9%) in the 30–35 years group. A significant difference in IVM rates was noted between the age extremes – the very young (1–5 years) and the oldest (30–35 years) groups, as compared with the 18–24-year group (p < 0.001). Importantly, number of oocytes matured, percent of patients with matured oocytes, and overall maturation rate differed significantly (p < 0.001). Our finding of extremely low success rates in those very young (under 6 years) and older (≥30 years) patients suggests that oocytes retrieved during OTC prior to chemotherapy have an optimal window of age that shows higher success rates, suggesting that oocytes may have an inherent tendency toward better maturation in those age groups. |
format | Online Article Text |
id | pubmed-8250136 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82501362021-07-03 Age-Dependent in vitro Maturation Efficacy of Human Oocytes – Is There an Optimal Age? Karavani, Gilad Wasserzug-Pash, Peera Mordechai-Daniel, Talya Bauman, Dvora Klutstein, Michael Imbar, Tal Front Cell Dev Biol Cell and Developmental Biology In vitro maturation of oocytes from antral follicles seen during tissue harvesting is a fertility preservation technique with potential advantages over ovarian tissue cryopreservation (OTC), as mature frozen and later thawed oocyte used for fertilization poses decreased risk of malignant cells re-seeding, as compared to ovarian tissue implantation. We previously demonstrated that in vitro maturation (IVM) performed following OTC in fertility preservation patients, even in pre-menarche girls, yields a fair amount of oocytes available for IVM and freezing for future use. We conducted a retrospective cohort study, evaluating IVM outcomes in chemotherapy naïve patients referred for fertility preservation by OTC that had oocyte collected from the medium with attempted IVM. A total of 133 chemotherapy naïve patients aged 1–35 years were included in the study. The primary outcome was IVM rate in the different age groups – pre-menarche (1–5 and ≥6 years), post-menarche (menarche-17 years), young adults (18–24 years) and adults (25–29 and 30–35 years). We demonstrate a gradual increase in mean IVM rate in the age groups from 1 to 25 years [4.6% (1–5 years), 23.8% (6 years to menarche), and 28.4% (menarche to 17 years)], with a peak of 38.3% in the 18–24 years group, followed by a decrease in the 25–29 years group (19.3%), down to a very low IVM rate (8.9%) in the 30–35 years group. A significant difference in IVM rates was noted between the age extremes – the very young (1–5 years) and the oldest (30–35 years) groups, as compared with the 18–24-year group (p < 0.001). Importantly, number of oocytes matured, percent of patients with matured oocytes, and overall maturation rate differed significantly (p < 0.001). Our finding of extremely low success rates in those very young (under 6 years) and older (≥30 years) patients suggests that oocytes retrieved during OTC prior to chemotherapy have an optimal window of age that shows higher success rates, suggesting that oocytes may have an inherent tendency toward better maturation in those age groups. Frontiers Media S.A. 2021-06-18 /pmc/articles/PMC8250136/ /pubmed/34222236 http://dx.doi.org/10.3389/fcell.2021.667682 Text en Copyright © 2021 Karavani, Wasserzug-Pash, Mordechai-Daniel, Bauman, Klutstein and Imbar. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cell and Developmental Biology Karavani, Gilad Wasserzug-Pash, Peera Mordechai-Daniel, Talya Bauman, Dvora Klutstein, Michael Imbar, Tal Age-Dependent in vitro Maturation Efficacy of Human Oocytes – Is There an Optimal Age? |
title | Age-Dependent in vitro Maturation Efficacy of Human Oocytes – Is There an Optimal Age? |
title_full | Age-Dependent in vitro Maturation Efficacy of Human Oocytes – Is There an Optimal Age? |
title_fullStr | Age-Dependent in vitro Maturation Efficacy of Human Oocytes – Is There an Optimal Age? |
title_full_unstemmed | Age-Dependent in vitro Maturation Efficacy of Human Oocytes – Is There an Optimal Age? |
title_short | Age-Dependent in vitro Maturation Efficacy of Human Oocytes – Is There an Optimal Age? |
title_sort | age-dependent in vitro maturation efficacy of human oocytes – is there an optimal age? |
topic | Cell and Developmental Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8250136/ https://www.ncbi.nlm.nih.gov/pubmed/34222236 http://dx.doi.org/10.3389/fcell.2021.667682 |
work_keys_str_mv | AT karavanigilad agedependentinvitromaturationefficacyofhumanoocytesisthereanoptimalage AT wasserzugpashpeera agedependentinvitromaturationefficacyofhumanoocytesisthereanoptimalage AT mordechaidanieltalya agedependentinvitromaturationefficacyofhumanoocytesisthereanoptimalage AT baumandvora agedependentinvitromaturationefficacyofhumanoocytesisthereanoptimalage AT klutsteinmichael agedependentinvitromaturationefficacyofhumanoocytesisthereanoptimalage AT imbartal agedependentinvitromaturationefficacyofhumanoocytesisthereanoptimalage |